Concord Biotech Peer Comparison

NSE: CONCORDBIO | BSE: 543960

₹1,481.10

₹-0.80 (-0.05%)

As on 28-Aug-2026IST

Market cap

₹15,507 Cr

Revenue (TTM)

₹1,108 Cr

P/E Ratio

56.3

P/B Ratio

7.5

Div. Yield

0.5 %

Edit

	Concord Biotech	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Market cap (₹ Cr)	15,507	35,497	29,798	16,589	13,020
Revenue (₹ Cr)	1,108	9,683	2,372	2,590	676
Net Profit (₹ Cr)	270.18	1,018.97	497.77	603.02	183.60
Net Margin (%)	23.29	10.47	20.72	22.63	26.06
RoE (%)	14.45	21.30	28.49	19.61	22.72
Price to Earnings	56.31	35.10	59.86	27.51	71.29
Price-To-Book	7.48	6.77	14.74	4.76	14.09

Income Statement (₹ Cr)

	Concord Biotech	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Operating Revenue	1,108.39	9,683.45	2,371.81	2,590.40	675.61
Total Income	1,159.90	9,730.84	2,402.61	2,664.23	704.48
Total Expenditure	720.01	7,739.53	1,608.91	1,753.71	442.67
EBITDA	388.38	1,943.92	762.90	836.69	232.94
Depreciation	74.78	425.10	98.11	78.88	15.56
EBIT	313.60	1,518.82	664.79	757.81	217.38
Interest	0.26	148.45	26.33	5.43	7.96
Other Income	51.50	47.39	30.80	73.83	28.87
Exceptional Items	-3.28	-27.85	0.00	-25.66	0.00
Profit before Tax	361.56	1,389.91	669.26	800.55	238.30
Provision for Tax	91.39	370.94	171.48	197.53	54.69
Profit after Tax	270.18	1,018.97	497.77	603.02	183.60

	Concord Biotech	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Shareholder's Funds	2,017.06	4,950.03	1,874.47	3,332.13	883.34
Minority Interest	2.51	-7.58	0.00	0.00	-0.97
Non-Current Liabilities	50.51	723.57	345.47	142.73	74.82
Current Liabilities	169.08	3,912.24	710.20	508.04	201.96
Total Liabilities	2,231.79	--	2,930.14	4,157.10	1,174.38

	Concord Biotech	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Non-Current Assets	957.22	3,392.16	1,290.62	1,321.38	477.92
Current Assets	1,250.11	5,612.10	1,483.13	2,649.36	623.97
Total Assets	2,231.79	--	2,930.14	4,157.10	1,174.38
Total Debt*	0.00	--	196.61	0.00	148.29
Net Current Assets	1,081.04	1,699.86	772.93	2,141.33	422.01
Contingent Liabilities	3.76	--	13.18	4.82	--

	Concord Biotech	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Cash From Operating Activities	266.88	--	346.68	565.41	69.55
Cash Flow from Investing Activities	-142.72	--	-423.73	-570.15	-330.93
Cash from Financing Activities	-112.88	--	20.98	-64.34	247.29
Net Cash Inflow / Outflow	11.28	--	-56.08	-69.08	-14.09

	Concord Biotech	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
ROCE (%)	18.04	--	27.50	24.61	28.50
ROE (%)	14.45	21.30	28.49	19.61	22.72
ROA (%)	12.66	11.42	19.48	16.31	31.25
EBIT Margin (%)	28.29	15.68	28.03	29.25	32.18
Net Margin (%)	23.29	10.47	20.72	22.63	26.06
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Concord Biotech	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Revenue Growth (%)	-6.72	18.36	78.33	7.93	23.56
EBIT Growth (%)	-26.64	30.43	303.07	19.88	12.00
Net Profit Growth (%)	-24.38	32.39	182.61	21.66	20.07
EPS Growth (%)	-21.99	36.68	277.72	25.42	50.65
Book Value Growth (%)	11.27	--	22.95	18.43	79.97

	Concord Biotech	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Price / Earnings	55.82	34.38	59.86	26.64	68.52
Price / Book Value	7.48	6.77	14.74	4.76	14.09
Dividend Yield (%)	0.51	0.19	0.15	0.37	0.13
EV/EBITDA	38.86	18.51	38.85	18.89	56.04
Market Cap (₹ Cr)	10,627.92	--	15,412.11	11,956.86	6,690.53

	Concord Biotech	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Debt to Equity	0.00	0.05	0.09	0.00	0.04
Short term debt to equity ratio	--	--	--	--	0.12
Current Ratio	7.39	1.43	2.09	5.21	3.09
Quick Ratio	5.46	0.82	1.37	3.85	2.02
Interest Coverage	1,386.30	10.36	26.41	148.49	30.94

	Concord Biotech	Emcure Pharmaceuticals	Neuland Lab	Alivus Life Sciences	Sudeep Pharma
Debtors to sales (%)	41.52	26.46	22.82	41.42	33.68
Asset Turnover	0.52	1.09	0.93	0.70	1.15
Receivable days	169.86	--	77.32	144.58	115.16
Inventory Days	97.92	--	80.83	96.67	96.15
Payable days	159.68	--	125.94	135.45	106.08
Cash Conversion Cycle	108.11	--	32.22	105.80	105.23

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.